Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Immunoncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for KLRC2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | KLRC2 ECD-Fc / Heterodimer Recombinant Protein High purity (>95%), Endotoxin Controlled (<1 EU/ug). Sequence Verified. HEK293 expressed for native glycosylation. |
View KLRC2 Products |
| Gene Delivery | KLRC2 Promise-ORF / Lentivirus Premade Particles Full-length ORF for stable cell line construction and cell-based functional assays. |
View KLRC2 Products |
| Benchmark Ab | Anti-KLRC2 Recombinant Antibody Recombinant positive control derived from clinical-stage benchmark sequences. |
View KLRC2 Products |
| Validator | KLRC2 siRNA Set Target-specific knockdown pool for functional validation and specificity controls. |
View KLRC2 Products |
| Related Target A | KLRD1 (CD94) Obligate heterodimerization partner required for functional assembly and HLA-E ligand recognition. |
View KLRD1 Products |
| Related Target B | KLRC1 (NKG2A) Inhibitory homolog sharing high sequence identity; essential for counter-screening to ensure selectivity. |
View KLRC1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Heterodimer Formation Requirements | Co-expressed KLRC2/KLRD1 heterodimer proteins available with verified stoichiometric ratios. |
| Subfamily Counter-Screening (NKG2A vs. NKG2C) | High-purity KLRC1 (NKG2A) recombinant proteins for rigorous cross-reactivity profiling. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay calibration. |
| False Positives | Sequence-verified siRNA pools included for target-specific knockdown validation. |
Live KLRC2/CD159c R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for KLRC2 (NKG2C) therapeutics is intensifying, with major players shifting focus from traditional mAbs to multi-specific NK cell engagers (NKCEs) and CAR-NK cell therapies. As first-generation therapies reach the clinic, the next wave of R&D is targeting optimized activation pathways without triggering off-target exhaustion or cross-reacting with the inhibitory counterpart, NKG2A.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| NK Cell Engager (NKCE) | Innate Pharma, Sanofi | Hematological Malignancies, Solid Tumors | Affinity & Selectivity Assay (Need high-purity KLRC2 and KLRC1 proteins) |
| Monoclonal Antibody (Agonist) | ImmuneOnco, Shattuck Labs | Advanced Solid Tumors | Epitope Mapping & Cross-reactivity (Need Cynomolgus/Human orthologs) |
| CAR-NK Cell Therapy | Artiva Biotherapeutics, Nkarta | Refractory Lymphomas | Stable Surface Expression (Need Lentivirus for stable CD94/NKG2C cell lines) |